Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes
Shamir N Kalaria,1 Deanna L Kelly21Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA; 2Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Deann...
Enregistré dans:
Auteurs principaux: | Kalaria SN, Kelly DL |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2e45f311c95b432ea81d205bc7dba4ec |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
par: Fitri Fareez Ramli, et autres
Publié: (2021) -
Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia
par: Amina Aissa, et autres
Publié: (2022) -
A survey of personnel and services offered in 32 outpatient US clozapine clinics
par: Robert O. Cotes, et autres
Publié: (2021) -
Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile
par: de Filippis R, et autres
Publié: (2021) -
Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides
par: Li Y, et autres
Publié: (2017)